|Trade names||originally Neulasta, other brand names worldwide|
|Elimination half-life||15–80 hrs|
|Chemical and physical data|
|Formula||C845H1343N223O243S9 + PEG|
|Molar mass||39,000 g/mol g·mol−1|
|(what is this?)|
Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.
In the United States as of 2015 the branded form costs between $5,327 and $8,191 a dose.
As of 22 September 2015 a 6 mg/0.6 ml dose costs $15,016.29 in the United States.
On November 2, 2018 Coherus Biosciences received FDA approval for its biosimilar, Udenyca. The push to receive approval and begin production of Udenyca was due in large part to the quickly increasing cost of Neulasta, which has nearly tripled since its release in 2002.
- Drugs.com International brand names for pegfilgrastim Page accessed April 1, 2016
- Walsh, G, Spada, S. "Epogen/Procrit" in: Directory of approved biopharmaceutical products. CRC Press, 2005, pp. 136–37.
- Drugs.com: Pegfilgrastim
- Ho, R.J.Y., Gibaldi, M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs Wiley-IEEE, 2003, pp. 139, 158.
- Langreth, Robert (June 29, 2016). "Decoding Big Pharma's Secret Drug Pricing Practices". Bloomberg. Retrieved 15 July 2016.
- US FDA rejects Sandoz’s Neulasta biosimilar. 19 July 2016
- "FDA Approves Coherus' Pegfilgrastim Biosimilar, Udenyca".
- Neulasta full prescribing information
- Neulasta Onpro kit Healthcare Provider Instructions for Use
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|